Novartis and WHO Extend Partnership to Eliminate Leprosy, Treat 1 Million More by 2030

Novartis and WHO have renewed their partnership to eliminate leprosy, aiming to treat one million more people by 2030 and prevent countless new cases. The partnership has already reduced cases by over 95% since the introduction of multidrug therapy in the 1980s. Novartis will provide MDT globally at no cost and funding for a compound to serve as post-exposure prophylaxis.